Compare NSP & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NSP | CMPS |
|---|---|---|
| Founded | 1986 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 834.9M | 788.9M |
| IPO Year | 1996 | 2020 |
| Metric | NSP | CMPS |
|---|---|---|
| Price | $21.86 | $6.62 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $47.67 | $27.14 |
| AVG Volume (30 Days) | 1.2M | ★ 4.4M |
| Earning Date | 05-12-2026 | 01-01-0001 |
| Dividend Yield | ★ 10.78% | N/A |
| EPS Growth | N/A | ★ 0.86 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $6,812,000,000.00 | N/A |
| Revenue This Year | $4.27 | N/A |
| Revenue Next Year | $5.43 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.51 | N/A |
| 52 Week Low | $20.42 | $2.25 |
| 52 Week High | $93.81 | $8.90 |
| Indicator | NSP | CMPS |
|---|---|---|
| Relative Strength Index (RSI) | 26.95 | 45.47 |
| Support Level | N/A | $5.95 |
| Resistance Level | $48.32 | $7.02 |
| Average True Range (ATR) | 1.39 | 0.52 |
| MACD | 0.35 | -0.10 |
| Stochastic Oscillator | 20.04 | 8.61 |
Insperity Inc is a company that provides a wide range of human resources and business solutions designed to help businesses improve their performance. Small and midsize enterprises are the company's primary target customers. Majority of the company's products are offered through the company's Workforce Optimization and Workforce Synchronization solutions, which comprise various human resource functions, such as payroll and employment administration, employee benefits and compensation, government compliance, performance management, training and development services, and human capital management. The company generates all of its revenue in the United States.
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.